BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing for the ...
A new crop of AI browsers, notably OpenAI’s ChatGPT Atlas and Perplexity’s Comet, is available to users. But privacy concerns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback